| Gene symbol | CD274 | Synonyms | B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 | Type of gene | protein-coding |
| Chromosome | 9 | Map location | 9p24.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD274 molecule | ||||
| GTO ID | GTC2663 |
| Trial ID | NCT04847466 |
| Disease | Gastroesophageal Cancer | Head and Neck Squamous Cell Carcinoma |
| Altered gene | PD-L1 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-NK cell |
| Treatment | PD-L1 t-haNK |
| Co-treatment | Pembrolizumab, N-803 |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer |
| Year | 2021 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 10000096|000096-C |
| Cohort 1 | |||||||||
|
|||||||||